GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apnimed, Inc. granted 14 new non-executive employees 331,000 non-qualified stock options to purchase common stock under its 2026 Inducement Plan.
The stock options carry an exercise price of $15.40 per share, matching the closing trading price on the grant date of November 2, 2026.
Vesting terms require one-fourth of the shares to vest on the first anniversary of each employee's start date, with the remainder vesting in equal monthly installments over the next three years.
These awards were provided as inducement material for new hires in compliance with Nasdaq Listing Rule 5635(c)(4).
The 2026 Inducement Plan was adopted by the Apnimed board of directors on August 21, 2026.
Apnimed is advancing its product candidate AD109, designed to improve oxygenation in individuals with obstructive sleep apnea (OSA).
The company envisions novel oral therapies simplifying intervention & expanding treatment reach for OSA beyond current device or surgical options.